Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.50 |
| ▸ | FNTB | P49356 | 13/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128690 | 0.84 | GRIA2 (0.54) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL2680927 | 0.84 | GRIA2 (0.56) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL3403394 | 0.83 | FNTA (0.59) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL17244482 | 0.82 | GRIA4 (0.47) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL3131141 | 0.82 | GRIA4 (0.72) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL3131147 | 0.80 | GRIA2 (0.49) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL8282864 | 0.79 | GRIA2 (0.48) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL3402838 | 0.77 | PIK3CA (0.58) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL623756 | 0.75 | L3MBTL1 (0.47) | FNTAFNTBGRIA2GRIA4ALDH1A1 | |
| SCHEMBL26664883 | 0.72 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2250160-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | FNTA 3475/4885FNTB 3949/4885GRIA2 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.